Marijus Valatka, general manager Lithuania, Latvia and Estonia at Novo Nordisk, explains the current challenges and areas for improvement in diabetes treatment in Lithuania and stresses the company’s commitment to not only bring medicines to the market but also enhance the quality of treatment fort diabetes and other serious chronic diseases such haemophilia, growth disorders, and obesity.
Before joining Novo Nordisk back in January 2016, you worked in leading generics and innovative players such as Teva and Servier. What are the factors that triggered you to move back to the innovative side of the pharmaceutical industry after more than three years at Teva?
"In terms of access to medicine in Lithuania, only 22 percent of all the innovative drugs that were centrally approved by the EMA from 2006 to 2015 reached Lithuanian patients."
